AbbVie in the news

AbbVie's high dividend payout is primarily supported by free cash flow and not reported earnings, due to significant non-cash expenses from acquisitions, and its financial structure is heavily leveraged with negative shareholders' equity.

AbbVie's stock is outperforming the S&P 500, with strong Q3 earnings expected, a low forward P/E multiple, and a solid dividend, making it an attractive investment.

AbbVie and Genmab announced positive Phase III trial results for epcoritamab combined with R-CHOP, showing significantly improved progression-free survival in newly diagnosed diffuse large B-cell lymphoma patients.

A combination of Epkinly, a bispecific antibody from Genmab and AbbVie, and chemotherapy demonstrated a nearly 50% reduction in disease progression or death risk in a Phase 3 trial for newly diagnosed lymphoma patients.

HSBC analyst Rajesh Kumar raised AbbVie's price target to $315 due to the strong performance and expanded indications of its drugs Skyrizi and Rinvoq, along with strategic acquisitions in immunology.

AbbVie and Merck offer attractive dividends, but AbbVie has new growing drugs to compensate for the expired Humira patent, while Merck faces a patent cliff with Keytruda.

Genmab and AbbVie announced their drug epcoritamab combined with standard chemotherapy significantly improved progression-free survival in a Phase 3 trial for diffuse large B-cell lymphoma patients.

Genmab's new drug, Rina-S, showed better efficacy and safety than AbbVie's Elahere for ovarian cancer, leading analysts to predict higher sales for Rina-S despite a legal dispute.

AbbVie successfully navigated its patent cliff with new drugs, leading to revenue growth, while Bristol Myers Squibb, despite facing upcoming patent expirations, has higher net margins and a lower valuation.

AbbVie's stock shows strong growth and is considered undervalued by some, driven by new drug approvals and pipeline data, despite a high P/E ratio and future risks.

AbbVie received FDA approval for Juvmo, a once-daily Parkinson's disease pill, bolstering its neuroscience pipeline and diversifying its drug portfolio.

AbbVie completed a real-world observational study in Greece for its leukemia drug Venetoclax, assessing its safety and effectiveness in adult AML patients.

AbbVie is announcing its third-quarter 2026 financial results on October 30, 2026, via a webcast.

AbbVie's Rinvoq shows continued long-term efficacy in improving facial and total body repigmentation for vitiligo patients in phase 3 studies.

BofA increased price targets for AbbVie and J&J, with a stronger conviction for AbbVie due to its growth in Skyrizi and Rinvoq, strategic acquisitions, and favorable patent timeline.

AbbVie and Bristol Myers Squibb present contrasting financial profiles for 2026, with AbbVie showing strong growth in immunology and aesthetics, while Bristol Myers Squibb leverages oncology and hematology amid legal challenges.

AbbVie's eczema drug shows promise in Phase 2, while BioMarin implements layoffs.

AbbVie's investigational drug ABBV-295 showed up to 9.8% weight loss in Phase 1 trials for obesity.

Investment analysts on CNBC's "Halftime Report Final Trades" recommended UnitedHealth, AbbVie, and Okta, with AbbVie recently receiving FDA approval for a Parkinson's drug.

AbbVie, a large pharmaceutical company, remains a stable investment due to new drug launches and acquisitions offsetting Humira's patent loss, with projected growth despite not being a top stock pick.